Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
ZLAB
Zai Lab Limited
Active antibody-drug conjugate (ADC) development including DLL3 and LRRC15 ADC programs.
|
$1.91B |
$17.09
-1.41%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.89B |
$41.38
-3.23%
|
|
TWST
Twist Bioscience Corporation
Twist's antibody libraries for drug discovery align with the Antibody Discovery Platform investable theme.
|
$1.88B |
$30.40
-2.16%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.84B |
$36.70
+0.58%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$1.82B |
$6.87
-2.21%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.82B |
$4.18
-0.48%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.81B |
$35.92
-0.28%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$1.81B |
$32.83
-0.47%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.80B |
$26.58
-1.88%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$1.80B |
$21.18
+1.44%
|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.77B |
$81.97
+0.56%
|
|
PRGO
Perrigo Company plc
Digestive Health OTC products are a significant Perrigo self-care category.
|
$1.77B |
$12.89
+0.39%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.74B |
$39.75
+0.10%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.69B |
$45.82
+0.26%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.65B |
$40.66
-0.02%
|
|
AZTA
Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
|
$1.61B |
$34.82
-0.74%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$1.59B |
$7.48
-1.45%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.57B |
$5.74
-0.43%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Lead assets PYRUKYND (mitapivat) and tebapivat are oral small-molecule PK activators targeting red blood cell metabolism in rare hematologic diseases, representing Agios's core product strategy.
|
$1.56B |
$26.18
-2.50%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.54B |
$48.48
-1.08%
|
|
NEO
NeoGenomics, Inc.
MRD-related diagnostics and companion diagnostics align with therapy selection and monitoring.
|
$1.54B |
$11.69
-1.97%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.54B |
$12.62
+0.08%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.49B |
$6.12
-1.37%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.47B |
$27.17
-0.11%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$1.46B |
$8.70
+2.59%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.45B |
$18.60
-2.16%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.45B |
$16.16
+0.59%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.37B |
$35.02
+7.46%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.35B |
$40.54
-3.29%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.34B |
$17.94
-1.48%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.30B |
$24.05
+0.61%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.28B |
$44.50
-2.33%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.27B |
$10.79
-0.60%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.27B |
$20.27
+0.65%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.22B |
$25.53
-2.96%
|
Showing page 7 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
